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HIV resistance to antiretroviral agents is a major
contributory cause of treatment failure. The dynamics
of HIV replication, together with patient-, physician-,
and drug-related factors, lead to emergence of HIV re-
sistant strains in most of the patients.
 Phenotypic assays look for an increase in the
antiretroviral drug (ARV) concentration that inhibits
50% of the growth of the tested HIV strain (IC50), com-
paratively with a reference strain cultivated in parallel.
Genotypic tests detect resistance mutations in the
reverse transcriptase and protease genes by comparing
the gene sequences of a resistant virus to those of a wild-
type strain that has previously been described. The effi-
cacy of each ARV class and each individual ARV is
threatened by specific mutations and resistance mecha-
nisms. In retrospective studies of genotypic or
phenotypic resistance testing, baseline resistance tests
results were correlated with virological outcomes. There
is some evidence from prospective studies that resist-
ance testing may have some benefits when used to
choose salvage regimens. However, problems in the ar-
eas of test interpretation, patient compliance, availabil-
ity of active drugs, and technical test performance limit
the usefulness of resistance testing in clinical practice.
This article reviews the mechanisms underlying HIV
resistance, the principles of phenotypic and genotypic
tests, and the use of these tests in clinical practice.
INTRODUCTION
In many HIV-infected patients, highly active
antiretroviral therapy (HAART) consisting in combina-
tions of potent antiretroviral drugs (ARVs) (1-4) can
diminish the plasma viral load (HIV RNA concentra-
tion) to undetectable levels, thereby noticeably reduc-
ing HIV-related morbidity and mortality (5). Unfortu-
nately, after one year of HAART, only 50 to 70% of
patients enrolled in therapeutic trials still had
undetectable viral loads (6). Virological failure, defined
as resumption of measurable viral replication, is even
more common in everyday clinical practice, particularly
among patients who are experienced with ARV therapy
(7). Many risk factors for virological failure are inher-
ent in the virus itself, but others are related to the ARVs,
the physicians, or the patient (Table I) (8,9). The emer-
gence of viral mutations associated with drug resistance
is a pivotal phenomenon that is both a major cause of




All developing organisms tend to escape from envi-
ronmental pressures by selective replication of adapted
strains rather than of susceptible strains. This natural
192
Acta Clinica Belgica, 2002; 57-4
HIV RESISTANCE TO ANTIRETROVIRAL DRUGS: MECHANISMS, GENOTYPIC
AND PHENOTYPIC RESISTANCE TESTING IN CLINICAL PRACTICE
selection process is a well-known cause of bacterial re-
sistance to antimicrobial agents. Natural selection oc-
curs at a particularly fast pace among HIV strains ex-
posed to ARVs because of its high turnover associated
with a high degree of genetic diversity (quasi-species)
as in other lentiviruses. The propensity for mutations
that underlies this genetic diversity is related to the high
rate of reverse transcriptase errors, the absence of mecha-
nisms for correcting these errors, and the rapid replica-
tion rates of HIV (10). This leads to the constitution of
an extremely heterogeneous mixture of clones (quasi-
species). The probability that one of these clones will
be resistant to one or more ARVs is high. Mutations that
confer ARV resistance, called primary mutations, usu-
ally slow the rate of viral replication of the affected strain
(decreased fitness). Consequently, the prevalence of pri-
mary resistant viruses in a given patient before treat-
ment is usually low: the variants with resistance muta-
tions constitute small minorities within the quasi-spe-
cies mixture. However, when treatment is started, the
ARVs select these variants, whose speed of emergence
depends both on the pre-treatment prevalence of the
mutation and on the relative replicative advantage the
mutation confers to the virus in the presence of the ARV
(11). This measurable resumption of replication allows
the virus to acquire not only other primary mutations
but also secondary mutations that restore its replication
potential, increasing the viral load (12). Primary and
secondary mutations both occur in the genes encoding
the reverse transcriptase (RT) and the protease (PR),
which are the targets of currently available ARVs.
The risk of mutation emergence is correlated with
the viral load under treatment (13). When the virus rep-
licates more slowly (producing a low concentration of
viral RNA), the risk that a resistance will emerge is
smaller. On the contrary, a high viral load will be asso-
ciated with an increased replication rate and a higher
risk of emergence of resistance. Nevertheless, even with
optimal treatment and a viral load below detectable lev-
els, viral replication never stops completely. It follows
that emergence of variants with resistance to ARVs is
quite inevitable (14).
ARV RESISTANCE TESTS
The first report of HIV resistance to an ARV was a
1989 paper by Larder et al. describing phenotypically
reduced susceptibility to zidovudine of HIV isolated
during prolonged therapy (15). The genetic basis for this
resistance was rapidly identified by comparisons of nu-
cleotide sequences from resistant and susceptible viral
strains (16). The mutations found within the RT gene
showed some degree of reproducibility, allowing the
development of rapid tests for detecting resistance to
zidovudine, the only ARV available at the time.
“Genotypic resistance” is defined as the presence of
mutations within the RT or P gene of viruses from pa-
tients experiencing virological failure or from labora-
tory HIV strains examined after subculturing with in-
creasing drug concentrations. These mutations are iden-
tified by comparison with wild-type virus. Increase in
the drug concentration that inhibits 50 percent (IC50)
of growth of the tested HIV strain compared to that of a
wild-type strain cultivated in parallel at varying drug
concentrations defines the “phenotypic resistance”.
TABLE I. Factors that contribute to failure of ARV
therapy (8,9) or disease progression
Virus-related factors
- development of resistance to ARVs
- transmission of virus resistant to ARVs
- emergence of syncytium-inducing virus
- genetic polymorphisms (?)
ARV-related factors
- limited potency of ARVs
- poor penetration into sanctuaries (central nervous
system, male genital tract, foetus…)
- drug-drug interactions
Physician-related factors
- choice of an inadequate ARV combination
- failure to perform or adequately use ARV resist-
ance testing
- failure to assay ARVs
- failure to prevent side-effects
Patient-related factors
- poor adherence with therapy
- genetic heterogeneity of the co-receptors CCR5
and CXCR4
- efficacy of intracellular NRTI phosphorylation
- presence of cellular membrane-spanning proteins
responsible for PI efflux
- ARV absorption/metabolism
- gradual immunological decline
(?) : Not fully demonstrated
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Tests for genotypic resistance
Testing for genotypic resistance involves examina-
tion of viral genome sequences amplified by the
polymerase chain reaction (PCR). The virus is taken
from the plasma of the patient. Mutations previously
shown to confer resistance documented by phenotypic
tests are looked for either by sequencing the entire RT
and P genes or by examining specific codons for point
mutations known to be associated with the emergence
of resistance (17). Two sequencing kits (Visible Genet-
ics‚, and Applied Biosystems‚) and one point mutation
detection kit (Innogenetics‚) are commercially available.
However, many virology laboratories have developed
their own home-brew sequencing methods. The main
difficulty in genotypic resistance testing is the interpre-
tation of the mutations. Different algorithms have been
produced to automatically interpret the genetic sequence.
For most drugs, a similar resistance interpretation was
obtained when comparing 5 genotypic resistance inter-
pretation algorithms. However, the algorithms largely
diverge in the interpretation of resistance to stavudine,
didanosine, and zalcitabine (18).
Tests for phenotypic resistance
Tests for phenotypic resistance consist in measuring
the in vitro replication of the virus in the presence of
varying concentrations of a given ARV. The ARV con-
centration needed to reduce replication by 50% (IC50)
or 90% (IC90) is determined; thus, this method is analo-
gous to determination of the minimal inhibitory con-
centration of an antimicrobial for a bacterial organism.
Although the results can be expressed as absolute val-
ues (e.g., IC50=800 nM for the ARV X), they are usually
reported as a comparison with the inhibitory concentra-
tion for a wild-type virus that serves as the reference
(e.g., a strain with an IC50 of 800 nM for ARV X is re-
ported as having eight-fold reduced susceptibility as
compared to a reference virus whose IC50 to the same
ARV is 100 nM).
In the past, phenotypic resistance was evaluated by
culturing virus from the patient in peripheral blood
mononuclear cells from healthy donors (19). This tech-
nique required 6 to 8 weeks, and the results varied with
the ability of the blood cells to support growth of the
HIV. These two problems have been overcome by the
development of tests using recombinant HIV clones in
which the RT and P genes are replaced by the corre-
sponding genes of the HIV strain under study previously
amplified by PCR on viral RNA harvested from the pa-
tient’s plasma (20). Three phenotypic tests based on
recombinant viruses are on the market (ViroLogic‚, San
Francisco; Virco‚, Malines; and VIRalliance‚, Paris).
Phenotyping requires high laboratory skills and high
security labs, which are not broadly available. Virco has
recently released new cut-offs deemed to be more bio-
logically relevant. Until now resistance tests have used
somewhat arbitrary cut-offs that were, for example,
based on the reproducibility of the tests themselves. The
limitation of setting a single cut-off for all available drugs
in this way is that it told the clinician very little about
the significance of any change in susceptibility reported
by a test, apart from it being large enough to be meas-
ured. In order to develop biologically relevant cut-off
values for each drug, the IC50 values for 1,000 untreated
patients as well as many thousands of samples of HIV-1
with no resistance mutations were measured (21). The
average and the range of susceptibility were calculated
for each drug. The cut-offs were then set at two stand-
ard deviations above the mean. This statistical term
means that a test result falling above the cut-off can be
said to be above the normal susceptible range with 97.5%
confidence. Since the susceptibility of untreated and un-
mutated virus varied considerably from drug to drug,
the new cut-offs are different for each drug. ViroLogic,
San Francisco, California, has also defined new cutoffs
based on clinical studies. Clinical cutoff values provide
a direct correlation between resistance test results and
clinical response. This means drug susceptibility stand-
ards based on actual clinical response to antiretroviral
drugs. To determine clinical cutoffs, drug susceptibility
is measured at treatment initiation. Treatment response,
such as change in viral load, is monitored at predeter-
mined study timepoints. Drug susceptibility is correlated
with treatment response. Clinical cutoff value is deter-
mined by resistance levels associated with treatment
failure (statistical analysis of overall trial results). Clini-
cal cutoff values are currently being evaluated for all
antiretroviral drugs, and are already available for Ziagen,
Kaletra, d4T and ddl (22).
Virtual Phenotype
Another way to improve interpretation of genotypic
informations is to confront them with phenotypic resist-
ance data. Genotyping is more rapid and less expensive
than phenotyping and, by detecting mutations in the
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genome, it can provide an early warning of potential
resistance, even if full resistance to one or more drugs
has not yet developed. The main limitation of genotyping
is that it is not a direct measure of resistance. A geno-
typic test can reveal the mutations that have occurred in
the relevant sequence of the HIV genetic code but then
this information requires interpretation to predict which
drugs the virus will and will not be sensitive to. With
genotypic testing systems this is done by reference to
lists of the main mutations and what effect they have on
susceptibility to HIV drugs. Interpreting this informa-
tion using tables or ‘rules-based’ algorithms, is difficult.
Another approach combining genotypic information and
phenotypic susceptibility has been developed. When a
genotype for a patient sample is generated the genetic
code for the RT-PR region is fed into a software system.
This system identifies all the mutations that can affect
resistance to each drug and then interrogates the data-
base for genotypes from previous samples that match
these patterns of mutations. When all the matches have
been identified, the software retrieves the phenotypes
for these samples and, for each drug, averages the data
for all the matches. This produces a VirtualPhenotype™,
with a fold change in IC50 for each drug. However, the
number of samples matching the sequence can be lim-
ited for complex mutation patterns. The caveats of in-
terpreting phenotypic resistance assays are also repro-
duced using this methodology. A study has shown the
equivalence of virtual phenotype compared to pheno-
type in the choice of salvage therapy in highly ARV ex-
perienced patients (23).
Advantages and disadvantages
Although they complement each other, genotypic and
phenotypic tests each have their own advantages and
disadvantages, which are listed in Table II. A study has
shown that these tests suffer from lack of standardiza-
tion: when specimens containing well-defined propor-
tions of mutant viruses were sent to various reference
laboratories, results in terms of sensitivity and specificity
of the resistant mutant strains varied widely across labo-
ratories (24). A new world-wide quality control has
shown an improvement in the technical aspects of geno-
typic resistance testing but large divergence in the defi-
nition of resistance across laboratories (25).
Furthermore, both categories of tests involve con-
version of RNA to DNA followed by PCR amplifica-
tion. These procedures require a viral load greater than
1000 copies/ml. The detection threshold for HIV RNA
is only 50 copies/ml. The HIV RNA concentration re-
quiring a change in treatment in clinical practice remains
to be defined but may be lower than 1000 copies/ml.
Phenotypic tests
Advantages
- evaluate the net effect of mutations on susceptibil-
ity to ARV therapy
- provide information on cross-resistance
- give results as the IC50, which is more familiar to
clinicians and, consequently, easier to interpret than
genotypic test results
- provide information on resistance to a given ARV
even when the genetic basis for that resistance has
not yet been elucidated
Disadvantages
- insensitive to presence of minority mutated strains
- costly
- so complex that availability is restricted to a few
laboratories
- for most ARVs, cutpoints defining resistance or sus-
ceptibility have not yet been established or vali-
dated
- several weeks required to obtain results
Genotypic tests
Advantages
- fairly simple to use
- widely available
- results available rapidly
- can detect sentinel mutations not yet apparent
phenotypically
Disadvantages
- not directly interpretable
- interpretation requires prior knowledge of the ge-
netic determinants responsible for resistance
- interpretation requires an expert
- insensitive to the presence of minority mutated
strains (point mutations assays are more sensitive
than sequencing assays (63))
- cannot predict the effects of mutation-mutation in-
teractions on the phenotype
 TABLE II. Advantages and disadvantages of geno-
typic and phenotypic resistance tests
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The correlation between genotypic resistance and
phenotypic resistance is poor for some nucleoside re-
verse-transcriptase inhibitors (NRTIs), fair for protease
inhibitors (PIs), and excellent for non-nucleoside re-
verse-transcriptase inhibitors (NNRTIs) (26) . This cor-
relation varies with the cutpoints chosen for phenotypic
testing and with the algorithm used for genotypic test-
ing.
Nature of and resistance to the various ARVs
The position and nature of the amino acid correspond-
ing to the mutated codon play a key role in the develop-
ment of resistance. The list of resistance mutations iden-
tified in vitro and/or in vivo is updated regularly (17),
producing an increasingly detailed map of viral resist-
ance. At the same time, our understanding of the mecha-
nisms by which mutations cause resistance to ARVs has
made huge strides. The three-dimensional structure of
the enzymes RT and P has been defined. The structural
enzyme changes generated by mutations and the effects
of these changes on the affinity of the enzyme for its
substrate, on its processivity, and on its mode of opera-
tion are gradually being elucidated.
Resistance to nucleoside reverse-transcriptase inhibitors
(NRTIs)
The mutations
As an example, we will discuss mutations that con-
fer resistance to zidovudine. Six substitutions, located
in codons 41, 67, 70, 210, 215, and 219 of the RT gene,
are known to confer resistance to zidovudine. These
mutations emerge in a given order (27). Only in this
order are the changes induced by the mutations consist-
ent with the physico-chemical laws governing biologi-
cal systems. Furthermore, this order of emergence is
associated with the smallest possible effect on RT func-
tion.
The earliest mutation affects codon 70 and can
emerge as early as 12 weeks after treatment initiation
(28) . The viral population harbouring this mutation is
rapidly replaced by more stable mutants, characterized
by a change in codon 215. Subsequently, the codon 70
mutation can reappear, and mutations can occur in
codons 41, 67, and 219. In most patients, the codon 210
mutation occurs fairly late. Each mutation and combi-
nation of mutations confers its own decrease in suscep-
tibility to zidovudine. Persistent viral replication in the
presence of zidovudine results in gradual accumulation
of mutations through a process of selection of the quasi-
species characterized by greater resistance and higher
replication potential, according to the Darwinian model
(1). These mutations make the HIV increasingly resist-
ant to zidovudine, so that viral replication persists and,
eventually, the resistance extends to other ARVs (cross-
resistance). It has now been shown that some mutations
confer resistance not only to zidovudine but also to d4T,
abacavir, and probably ddI. Thus, mutations that confer
resistance to thymidine analogs (thymidine analog mu-
tations, TAMs) cause resistance to quite all NRTIs (29).
In some cases, a single mutation results in resistance
to several or even all NRTIs. Two series of mutations
conferring resistance to all available NRTIs have been
identified. One is Q151M, which was first identified in
patients taking zidovudine in combination with
didanosine or zalcitabine (30) but since then has been
found in patients on other NRTIs. Q151M is the first
mutation to appear. It confers only small resistance on
its own. Mutations at codons 77, 116, 62, and 75 rapidly
develop which increase the resistance to zidovudine and
to the other NRTIs (30-31). Resistance increases with
the accumulation of the other mutations. Fewer data are
available on the other mutation responsible for resist-
ance to multiple NRTIs, T69S-SS. This mutation is char-
acterized by insertion in codon 69 of six nucleotides,
each of which encodes two serine residues. T69S-SS
occurs as a result of prolonged treatment with several
NRTIs, is less common than Q151M, and confers a high
level of resistance to all currently available nucleoside
and nucleotide analogues inhibitors of reverse tran-
scriptase (32). This resistance mutation generally ap-
pears on the background of one or more members of the
thymidine associated resistance mutations, particularly
the T215Y (33).
Genotypic analysis of resistances remains complex.
For instance, some mutations selected by one ARV re-
sult in resensitisation to another ARV to which the virus
had become resistant. An example is M184V, which
emerges during 3TC treatment but temporarily abolishes
the zidovudine resistance-conferring effect of mutation
T215Y (34).
The mechanisms
In parallel with the gradual accumulation of knowl-
edge on the positions and types of resistance mutations,
our understanding of the mechanisms underlying resist-
ance is improving. For instance, the mechanism by which
RT can become resistant to NRTIs has been elucidated.
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NRTIs, which are derivatives and analogues of natu-
rally occurring nucleosides, induce competitive inhibi-
tion of RT (2). Once inside the cell, NRTIs are phospho-
rylated to triphosphates then compete with endogenous
nucleosides for the RT catalytic site. When incorporated
in the elongating DNA strand, NRTIs block further elon-
gation, thereby halting viral replication. Thus, NRTIs
are chain terminators. The mutations responsible for
resistance to NRTIs act by modifying the three-dimen-
sional conformation of RT, which then preferentially uses
endogenous triphosphate deoxynucleosides: resistance
of the enzyme is related to better discrimination between
the natural substrate and the nucleoside analogue. This
is one of the mechanisms underlying resistance of RT
carrying the V75T mutation.
Another mechanism, called pyrophosphorolysis, has
been described recently. This mechanism may explain
the failure of some NRTIs to alter RT activity. As with
all chemical reactions, construction of a DNA strand is
a reversible process. In the presence of wild-type RT,
nucleotide incorporation, which releases pyrophosphate,
is strongly advantaged over nucleotide excision. How-
ever, some RT mutations make the enzyme capable of
using an ATP molecule or a previously released pyro-
phosphate molecule to enhance the excision function.
In this case, although excision remains disadvantaged
as compared to incorporation, chain terminators are ex-
cised more frequently and, consequently, are less effec-
tive (35). Increase in excision of chain terminators is
the main pathway for NRTIs resistance of a TAM bear-
ing RT. On the contrary, resensitisation to zidovudine of
RT bearing a TAM to which M184V is added (resist-
ance to 3TC) is related to a decrease in the
pyrophosphorolysis capacity of the mutated RT, which
can no longer excise the zidovudine incorporated at the
end of the chain. This temporarily restores susceptibil-
ity to zidovudine. The third identified mechanism for
RT resistance is an increase in processivity: all the func-
tions of the enzyme, incorporation and excision, are ac-
celerated.
Resistance to non-nucleoside reverse-transcriptase in-
hibitors (NNRTIs)
These ARVs also inhibit HIV replication by interfer-
ing with RT function, although they are structurally dif-
ferent from NRTIs. NNRTIs bind to the enzyme near its
catalytic site, causing non-competitive inhibition of DNA
strand polymerisation (36). In contrast to NRTIs, NNRTIs
are active without prior intracellular metabolic changes.
Major resistances to NNRTIs can develop rapidly,
sometimes within a few days of monotherapy initiation.
Resistance is related to point mutations, usually in
codons 98 to 108 or 181 to 190 of the RT. These muta-
tions change the RT site that binds to NNRTIs decreas-
ing its affinity for the compounds. K103N and Y181C
are the most common mutations. Although NNRTIs vary
widely in their chemical structure, cross-resistance is
common. This is a factor contra-indicating sequential
use of actual NNRTIs.
Interesting interactions between NRTIs and NNRTIs
have been reported. The Y181C mutation, which con-
fers resistance to NNRTIs, can increase viral suscepti-
bility to zidovudine (37). Conversely, some viruses re-
sistant to zidovudine and to abacavir show increased
susceptibility to NNRTIs (38), via an as yet unidenti-
fied mechanism. Larger studies would be useful to de-
termine the clinical relevance of these data.
Resistance to protease inhibitors (PIs)
The HIV protease (PR) is a homodimer composed
of two 99-residue chains. It cleaves transcribed viral
polyproteins into six structural proteins (p17, p24, p2,
p7, p1, and p6) and three enzymes (PR, RT, and
integrase), thus allowing viral assembly (39). PIs com-
pete with viral substrates for the active site of the PR.
Resistance mutations to PIs emerge slowly and
sequentially and are most common in patients with sub-
optimal plasma PI concentrations (40).
Although the P gene is small, more than 42 muta-
tions conferring resistance to PIs have been identified
(17). Some affect the substrate-binding site and cause
the resistance itself. Others are secondary mutations that
restore enzyme processivity, thus possibly enhancing the
activity of the mutated P without directly affecting its
binding to the inhibitor. Finally, other mutations, located
outside the P gene, can compensate for the functional
impairment in mutated P function. These last mutations
affect different sites of the polyprotein, particularly the
gag-pol cleavage site, where they restore sensitivity to
cleavage by the defective mutated protease (41).
As a rule, susceptibility to PIs decreases gradually
as mutations accumulate. Another effect of mutation
accumulation is broadening of the resistance to other
PIs, with cross-resistance or resistance to an entire class
of ARVs. Some mutations, for instance L90M or the
combination L10I + I84V, immediately confer a high
level of resistance to most PIs, without requiring the
accumulation of other mutations.
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Some RT gene mutations decrease RT activity,
thereby weakening the replication potential of the mu-
tated virus. This effect on replication seems even stronger
with some P gene mutations and probably explains why
some patients have fairly low viral loads despite a high
level of resistance (8). These mutations modify enzymes
that are crucial to HIV replication.
ARV resistance testing in clinical practice
a) Retrospective studies indicating that ARV resistance
testing is useful
In over a dozen retrospective studies, the informa-
tion provided by genotypic or phenotypic testing at treat-
ment initiation predicted virological outcomes (9). Fur-
thermore, the Resistance Collaborative Group used a
uniform framework to reappraise most retrospective and
prospective studies in which data on HIV resistance at
treatment initiation were available (42). The results
showed that HIV resistance to the drugs used predicted
virological success independently from other important
clinical data such as prior treatment or viral load.
b) Prospective studies using ARV resistance testing
Although there is a well-established association be-
tween resistance mutations and virological failure, the
contribution of resistance testing to the management of
patients experiencing virological failure is unclear. Sev-
eral prospective studies have addressed this issue (Ta-
ble IV) (43-50). Some found that resistance testing was
beneficial in the short-term, although the advantage was
fairly small (51). The viral load decrease in the group
that underwent resistance testing was about 0.5-0.6 log10
/ml, compared to the control group which is in the range
of the decrease obtained with NRTI monotherapy on a
wild-type strain. Similarly, the percentage of patients
with undetectable viral load in the study group was only
15 to 20% higher than in the control group. The differ-
ences in these parameters were statistically significant
in some studies but not in others (51,52).
Numerous limitations affect these findings. In addi-
tion to the shortcomings of the resistance tests them-
selves, limitations present in all prospective studies in-
cluded inadequacy of the interpretation algorithm avail-
able at the time, unavailability of drugs effective on re-
sistant viruses, and lack of experience of the investiga-
Study Design  VL Log10 % patients < Limiting factor
copies/ml detection limit studied
Viradapt* (43,53) Geno/SOC 1.04 vs. 0.46 29% vs. 14% Pharmacology
Vira 3001** (45) Pheno/SOC 1.72 vs. 2.21 45% vs. 34% -
GART* (46) Geno + E/SOC 1.19 vs. 0.61 34% vs. 22% Advice from a virologist
HAVANA* (39) SOC ±E/Geno±E 1.1 vs. 0.81 58% vs. 42% Advice from
21% vs. 17% an expert
ARGENTA (47) SOC + E/Geno + E NA 35% vs. 44% vs. 36%*** Compliance
Narval* (49) Geno/Pheno/SOC 1.1 vs. 1.0 vs. 0.7 NA*** Interpretation algorithm
Kaiser** (50) Pheno/SOC 0.4 vs. 0.2 -
*results after 12 weeks; **results after 16 weeks; ***p non-significant
Geno: group subjected to genotypic testing; Pheno: group subjected to phenotypic testing; SOC: standard of care; E: advice from
an expert;  VL: viral load difference between the tested group and the control group, in Log10 copies/ml; NA: not available
TABLE III. Prospective studies in which ARV resistance testing was done in patients experiencing virological
failure. From Demeter L (51)
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tors or failure to obtain expert advice (52). In some of
these studies, the reasons put forward to explain the small
magnitude of testing-related benefits highlight several
key aspects of patient management. For instance in the
GART (genotypic ARV resistance testing) study (46),
the patients whose physicians adapted the treatment ac-
cording to the advice of virologists had better virological
outcomes, as compared to the other patients. The ben-
efits of obtaining expert advice were particularly con-
spicuous in the HAVANA trial (47), in which patients
for whom expert advice was obtained were more likely
to have an undetectable HIV RNA load, independently
from whether genotypic testing was done. The
ARGENTA trial (48) examined the effect of treatment
compliance. Compliance of the patient with the treat-
ment was a better predictor of successful viral load sup-
pression than use of genotypic testing. The Viradapt trial
(53) highlighted the importance of the pharmacological
component as compared to resistance testing. Patients
whose treatment was adapted based on genotypic test
results and whose plasma PI concentrations were con-
sidered optimal were more likely to experience viral load
suppression than the other patient subgroups. Finally,
the Narval (49) trial pointed out the inadequacies of the
genotype interpretation algorithm.
Furthermore, the ARGENTA (48), Narval (49), and
Kaiser (50) studies showed that resistance testing was
less useful in patients with a history of multiple
virological failures. This is probably because no ARVs
effective on multiresistant HIV strains are available.
c) Limitations to the use of ARV resistance testing
Resistance tests themselves and their modalities of
use are still at the early stages of development. Quality
control studies have shown that resistance testing has
Limitations related to the tool
- PCR amplification possible only if viral load>1000 copies/ml
- less reliable if presence of non-B viral subtypes
- poor sensitivity for detecting minority strains contributing 20 to 50% of the overall mixture (>>>)
- the resistance analysis method has not been validated
- the assistance of an expert is needed to perform the test and to read the sequence
- costly
- no information available about the new ARV classes that will become available in the very near future (e.g.,
fusion inhibitors)
- testing explores only some HIV genes, providing no information on other regions (gag-pol) that are involved in
resistance
- mainly identifies drugs likely to be ineffective
- major discrepancies between phenotypic and genotypic results on susceptibility, especially for nucleoside ana-
logues
- does not take into account mutation-mutation interactions, which can result in resensitisation or in appearance of
another biological antiviral mechanism (effect on fitness, or pyrophosphorolysis for instance of mutation M184V)
- limited value in the event of planned or unplanned treatment discontinuation because misses resistances present
in minority strains or stored in proviral DNA incorporated in the cell genome
Limitations related to use of the genetic sequence result in clinical practice
- need for the advice of an expert in the clinical and treatment setting
- lack of clinical-virological correlation between presence of a given mutation and virological outcome under a
given drug (interpretation algorithms based on in vitro data and on clinical studies of monotherapy, whereas in
practice patients take drug combinations): inadequacy of interpretation algorithms
- lack of drugs effective on resistant viruses
- time lag between access to new drugs and knowledge of mutations conferring resistance to these drugs
TABLE IV. Limitations of genotypic tests related to the sequencing tool and to interpretation of results
199
Acta Clinica Belgica, 2002; 57-4
HIV RESISTANCE TO ANTIRETROVIRAL DRUGS: MECHANISMS, GENOTYPIC
AND PHENOTYPIC RESISTANCE TESTING IN CLINICAL PRACTICE
improved over time (24,25,54). Table IV lists remain-
ing shortcomings of the tests and their modalities of use.
Interpretation, the Achilles tendon of resistance test-
ing, is changing constantly. TAMs have been shown to
cause resistance not only to zidovudine but also to d4T
(55) and even to ddI (56). It has been suggested that
overuse of d4T and ddI in the genotypic testing group
of the Narval study was beneficial in that it reduced the
use of new ARVs; however, this may be a limitation to
the study, as the resistance test results were not used
optimally, according to current knowledge. The new
genotypic test interpretation algorithm developed by the
ANRS (Agence Nationale de Recherche sur le SIDA,
France) takes TAMs into account by indicating as the
result “resistance to zidovudine, d4T, and also ddI”. Data
from the analysis of virological outcomes in the control
arm of the Narval trial have been used to fine-tune the
interpretation of genotypic resistance to abacavir and
amprenavir (56).
d) Current recommendations regarding use of resistance
testing
The first consensus report about the indications for
ARV resistance testing was published in 1998 (57). The
increased availability of resistance tests and evidence
that these tests have some efficacy in clinical practice
have prompted the development of new recommenda-
tions in Europe (58-61) and in the United States (62).
The prevalence of the various HIV-1 subtypes, trans-
mission of resistant strains, availability of tests, reim-
bursement of tests by health care insurance, and many
other factors vary from one country to the next. Conse-
quently, each country has developed its own recommen-
dations. Table V shows the recommendations for Bel-
gium.
Testing is not recommended in chronically HIV-in-
fected patients prior to treatment initiation because the
resistant virus population possibly found in this situa-
tion is so small that it escapes isolation. Similarly, in
patients experiencing virological failure, resistance test-
ing should be done before the treatment is stopped or
changed, as afterwards the prevalence of the resistant
variants rapidly drops to undetectable levels.
CONCLUSION
The management of patients infected with the HIV
has made huge strides forward in the last few years,
particularly with the advent of new ARVs. The emer-
gence of viral variants that are resistant to ARVs is re-
lated not only to the high replication and mutation rates
of the HIV but also to poor compliance with therapy
and to use of insufficiently suppressive drug combina-
tions. Emergence of resistances remains the main ob-
stacle to long-lasting treatment success. Identifications
of viral mutations that confer specific resistance to a
given ARV should allow clinicians to choose the drug
combinations that maximally suppress viral replication.
Retrospective studies have shown that phenotypic or
genotypic viral resistance at treatment initiation pre-
dicted the virological response to the treatment used.
ARV resistance testing should be performed in situ-
ations such as those listed below:
1. Virological treatment failure, when a change in
treatment is being considered; the usefulness of
the resistance test will depend on remaining treat-
ment options. If the virus shows multidrug resist-
ance, the test will have little impact on treatment
decisions.
2. Treatment initiation in a child. Resistant strains
can be transmitted vertically.
3. Treatment initiation during pregnancy. Optimal
treatment is indispensable to minimize the risk of
vertical transmission.
ARV resistance testing should be considered in situ-
ations such as those listed below:
1. Treatment initiation in a treatment-naive patient.
Priority should be given to treatment-naive pa-
tients undergoing seroconversion, contamination
having apparently occurred in the recent past.
Detection of resistant mutants may be impossible
later during the course because of the decreased
replication potential of mutants. If testing is not
done at this time, plasma should be stored when-
ever possible.
2. Post-exposure prophylaxis. Every effort should be
made to obtain a sample from the HIV-infected
contact. Treatment cannot be postponed until the
results of ARV resistance testing are available but,
if needed, can be adapted based on the results.
TABLE V. Belgian recommendations for ARV resist-
ance testing (61)
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However, prospective studies of genotypic testing have
produced mixed results. Numerous limitations related
to the tests themselves and to the way they are used have
been recognized. Improvements in resistance testing, in
our knowledge of the mechanisms underlying resistance,
and in resistance test interpretation can be expected to
optimize ARV therapy in the near future. However, thera-
peutic failure is multifactorial. Therefore, multi-
disciplinary management of HIV infection should be the
reference standard and the most useful recommenda-
tion at present.
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